An Open-Label, Multicenter, Phase 1 Study of IGM-7354 in Adult Participants With Relapsed and/or Refractory Cancer
Latest Information Update: 23 Jan 2024
At a glance
- Drugs IGM 7354 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors IGM Biosciences
- 17 Jan 2024 Status changed from recruiting to active, no longer recruiting.
- 30 Mar 2023 According to an IGM Biosciences media release, company announced that it has successfully dosed two patients in this trial without any drug related safety issues to date
- 25 Jan 2023 Status changed from not yet recruiting to recruiting.